Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease

摘要: Increasing evidence supports a role for abnormal immune activation and inflammatory responses in Huntington disease (HD). In this study, we evaluated the therapeutic potential of laquinimod (1 10 mg/kg), novel immunomodulatory agent shown to be protective number neuroinflammatory conditions, YAC128 mouse model HD. Treatment with 6 months rescued atrophy striatum, certain cortical regions, corpus callosum HD mice. Diffusion tensor imaging showed that white matter microstructural abnormalities posterior were improved following treatment low dose (1 mg/kg) laquinimod, paralleled by reduced levels interleukin-6 periphery Functionally, 10 mg/kg) led modest improvements motor function depressive-like behaviour. Taken together, these results suggest may improve some features pathology HD, provides support pathogenesis